Abstract
Optimization of protein crystal formation is often a necessary step leading to diffraction-quality crystals to enable collection of a full X-ray data set. Typical protein crystal optimization involves screening different components, e.g., pH, precipitants, and additives of the precipitant solution. Here we present an example using an inhibitory antibody of urokinase plasminogen activator receptor (uPAR) where such procedures did not yield diffracting crystals. In contrast, it was the treatment of the protein with hydrogen peroxide incubation and the protein concentration reduction that were found to be key factors in obtaining diffracting crystals. Final crystals diffracted to 1.75 Å, and belong to orthorhombic P212121 space group with unit cell parameters a=37.162 Å, b=84.474 Å, c=134.030 Å, and contain one molecule of Fab fragment of anti-uro kinase receptor antibody in the asymmetric unit.
Keywords: hydrogen peroxide, crystal optimization, upar, antibody
Protein & Peptide Letters
Title: Optimization of Crystals of an Inhibitory Antibody of Urokinase Plasminogen Activator Receptor (uPAR) with Hydrogen Peroxide and Low Protein Concentration
Volume: 12 Issue: 7
Author(s): Yongdong Li, Xiaoli Shi, Graham Parry, Liqing Chen, Jennifer A. Callahan, Andrew P. Mazar and Mingdong Huang
Affiliation:
Keywords: hydrogen peroxide, crystal optimization, upar, antibody
Abstract: Optimization of protein crystal formation is often a necessary step leading to diffraction-quality crystals to enable collection of a full X-ray data set. Typical protein crystal optimization involves screening different components, e.g., pH, precipitants, and additives of the precipitant solution. Here we present an example using an inhibitory antibody of urokinase plasminogen activator receptor (uPAR) where such procedures did not yield diffracting crystals. In contrast, it was the treatment of the protein with hydrogen peroxide incubation and the protein concentration reduction that were found to be key factors in obtaining diffracting crystals. Final crystals diffracted to 1.75 Å, and belong to orthorhombic P212121 space group with unit cell parameters a=37.162 Å, b=84.474 Å, c=134.030 Å, and contain one molecule of Fab fragment of anti-uro kinase receptor antibody in the asymmetric unit.
Export Options
About this article
Cite this article as:
Li Yongdong, Shi Xiaoli, Parry Graham, Chen Liqing, Callahan A. Jennifer, Mazar P. Andrew and Huang Mingdong, Optimization of Crystals of an Inhibitory Antibody of Urokinase Plasminogen Activator Receptor (uPAR) with Hydrogen Peroxide and Low Protein Concentration, Protein & Peptide Letters 2005; 12 (7) . https://dx.doi.org/10.2174/0929866054696073
DOI https://dx.doi.org/10.2174/0929866054696073 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synergies of Targeting Angiogenesis and Immune Checkpoints in Cancer: From Mechanism to Clinical Applications
Anti-Cancer Agents in Medicinal Chemistry Semi-Synthetic Derivatives of Heliomycin with an Antiproliferative Potency
Recent Patents on Anti-Cancer Drug Discovery Prevention of Intracerebral Haemorrhage
Current Drug Targets RhoGEFs in Cell Motility: Novel Links Between Rgnef and Focal Adhesion Kinase
Current Molecular Medicine Muscle Metabolism and Exercise Capacity in Cachexia
Current Pharmaceutical Design Reactive Oxygen Species, Inflammation, and Lung Diseases
Current Pharmaceutical Design Glutathione for Hepatotoxicity in Patients with Liver Cirrhosis and Advanced Hepatocellular Carcinoma Receiving Hepatic Arterial Infusion Chemotherapy
Clinical Cancer Drugs Development of a Registry for Down Syndrome in the Gulf Area of the Middle East
Applied Clinical Research, Clinical Trials and Regulatory Affairs Ulipristal Acetate (Esmya) in the Management of Heavy Menstrual Bleeding Associated with Fibroids: A Case Series
Current Women`s Health Reviews Efficacy of High-Dose Vitamin D Supplementation in the Critically Ill Patients
Inflammation & Allergy - Drug Targets (Discontinued) Challenges and Opportunities in Molecular Imaging
Current Medical Imaging Synergistic Interaction of Telomerase-Specific Oncolytic Virotherapy and Chemotherapeutic Agents for Human Cancer
Current Pharmaceutical Biotechnology p53 Targeting Can Enhance Cancer Therapy via Radiation, Heat and Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Mechanisms of Allostery and Membrane Attachment in Ras GTPases: Implications for Anti-Cancer Drug Discovery
Current Medicinal Chemistry The Role of Carrier Geometry in Overcoming Biological Barriers to Drug Delivery
Current Pharmaceutical Design Preface
Mini-Reviews in Medicinal Chemistry Ethnopharmacological and Phytopharmaceutical Evaluation of Prosopis cineraria: An Overview and Future Prospects
Current Drug Metabolism Multidrug Resistance and Cancer: The Role of the Human ABC Transporter ABCG2
Current Protein & Peptide Science Medicinal Chemistry Meets Proteomics: Fractionation of the Human Plasma Proteome
Current Medicinal Chemistry Recent Findings Regarding Pathogenesis and Prevention of Ventilator- Associated Pneumonia
Current Respiratory Medicine Reviews